Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Summary
Biotech firm Moderna has upgraded its financial outlook, projecting higher revenue growth for the year 2026 than previously anticipated. The chief executive noted that the company's newer vaccine products are gaining stronger market momentum, prompting the upward revision in expected performance.
The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
Source: Read the full story at US Top News and Analysis
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.